Scott J. Diede - Concepedia

Author

Scott J. Diede

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

S. Diede, S. J. Diede, S.J. DIEDE, S.J. Diede, Scott Diede, Scott J Diede, Scott J. Diede

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)The University of Sydney Melanoma Institute Australia Fred Hutch Cancer Center University of Washington

About

Scott J. Diede is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	30	4.9K
2	Cell Biology	11	11	1.1K
3	Natural Sciences	9	9	1K
4	Health Sciences	7	7	1.1K
5	Social Sciences	1	1	25

Scott J. Diede

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy Antoni Ribas, Reinhard Dummer, Igor Puzanov, Cell Tumor ImmunologyAnti-pd-1 ImmunotherapyAutoimmune DiseaseCancer ImmunosurveillanceImmunology	2017	1.4K
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Georgina V. Long, Reinhard Dummer, Omid Hamid, The Lancet Oncology OncologyPembrolizumab Versus PlaceboMelanomaClinical TrialsMetastatic Melanoma	2019	899
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma Caroline Robert, Antoni Ribas, Omid Hamid, Journal of Clinical Oncology Durable Complete ResponseMedicineMelanomaImmunologyTumor Immunity	2017	477
Telomerase-Mediated Telomere Addition In Vivo Requires DNA Primase and DNA Polymerases α and δ Scott J. Diede, Daniel E. Gottschling Cell Genome InstabilityDna Polymerases αNatural SciencesGeneticsOligonucleotide	1999	381
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, The Lancet Oncology Interim AnalysisLymphoid NeoplasiaSurgical OncologyMedicineMelanoma	2019	324
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma Jason Chesney, Antoni Ribas, Georgina V. Long, Journal of Clinical Oncology	2022	241
The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku Suzanne E. Peterson, Anne E. Stellwagen, Scott J. Diede, Nature Genetics ChromatinGenome InstabilityChromatin RemodelingNatural SciencesGenetics	2001	230
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Journal for ImmunoTherapy of Cancer	2020	164
Exonuclease activity is required for sequence addition and Cdc13p loading at a de novo telomere Scott J. Diede, Daniel E. Gottschling Current Biology Long-read SequencingDna SequencingMolecular ResearchExonuclease ActivityNatural Sciences	2001	145
A duplication at chromosome 11q12.2-11q12.3 is associated with spinocerebellar ataxia type 20 Melanie A. Knight, Dena Hernández, Scott J. Diede, Human Molecular Genetics Sca20 RegionNeurodegenerative DiseasesDevelopmental BiologyMendelian DisorderGenetic Disorder	2008	138

Page 1